Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Maitland

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2010
Volumes to learn: advancing therapeutics with innovative computed tomography image data analysisMichael L Maitland
The Oncologist|March 15, 2013
More sound cancer therapy biomarker development with active noise controlMichael L Maitland
Clinical Advances in Hematology & Oncology : H&O|March 10, 2012
Advances in biomarkers for targeted agentsMichael L Maitland
Clinical Advances in Hematology & Oncology : H&O|August 4, 2016
Improving clinical trial design through quantitative pharmacologyMichael L Maitland
Clinical Advances in Hematology & Oncology : H&O|October 2, 2008
Cardiovascular toxicity of new agentsMichael L Maitland
Current Hypertension Reports|September 21, 2011
Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicityRajesh Gupta, Michael L Maitland
Annals of Internal Medicine|November 8, 2006
Terminal ballistics of kinase inhibitors: there are no magic bulletsMichael L Maitland, Mark J Ratain
Targeted Oncology|April 18, 2009
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitorsKelly L Snider, Michael L Maitland
The New England Journal of Medicine|February 1, 2003
Polymorphisms of adrenergic receptors and the risk of heart failureMichael L Maitland, Mardi Gomberg-Maitland
CA: a Cancer Journal for Clinicians|October 29, 2011
Clinical trials in the era of personalized oncologyMichael L Maitland, Richard L Schilsky
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2010
Volumes to learn: advancing therapeutics with innovative computed tomography image data analysisMichael L Maitland
The Oncologist|March 15, 2013
More sound cancer therapy biomarker development with active noise controlMichael L Maitland
Clinical Advances in Hematology & Oncology : H&O|March 10, 2012
Advances in biomarkers for targeted agentsMichael L Maitland
Clinical Advances in Hematology & Oncology : H&O|August 4, 2016
Improving clinical trial design through quantitative pharmacologyMichael L Maitland
Clinical Advances in Hematology & Oncology : H&O|October 2, 2008
Cardiovascular toxicity of new agentsMichael L Maitland
Current Hypertension Reports|September 21, 2011
Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicityRajesh Gupta, Michael L Maitland
Annals of Internal Medicine|November 8, 2006
Terminal ballistics of kinase inhibitors: there are no magic bulletsMichael L Maitland, Mark J Ratain
Targeted Oncology|April 18, 2009
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitorsKelly L Snider, Michael L Maitland
The New England Journal of Medicine|February 1, 2003
Polymorphisms of adrenergic receptors and the risk of heart failureMichael L Maitland, Mardi Gomberg-Maitland
CA: a Cancer Journal for Clinicians|October 29, 2011
Clinical trials in the era of personalized oncologyMichael L Maitland, Richard L Schilsky
Pageof 8